Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. Juni 2016 09:00 ET | Quelle: Emergent BioSolutions Inc.

Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine

GAITHERSBURG, Md., June 27, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has...
22. Juni 2016 08:32 ET | Quelle: Emergent BioSolutions Inc.

U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of Anthrax Vaccines

GAITHERSBURG, Md., June 22, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that on June 21, 2016, the U.S. Department of Health and Human Services (HHS) issued two...
21. Juni 2016 07:00 ET | Quelle: Emergent BioSolutions Inc.

FDA Completes Pre-Approval Inspection of Emergent BioSolutions’ Large-Scale Manufacturing Facility for BioThrax

GAITHERSBURG, Md., June 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval...
17. Juni 2016 07:00 ET | Quelle: Emergent BioSolutions Inc.

FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55

GAITHERSBURG, Md., June 17, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent’s...
15. Juni 2016 07:00 ET | Quelle: Emergent BioSolutions Inc.

Emergent BioSolutions Receives FDA Orphan Drug Status for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease

GAITHERSBURG, Md., June 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug status for...
05. Mai 2016 16:15 ET | Quelle: Emergent Biosolutions, Inc.

Emergent BioSolutions Reports First Quarter 2016 Financial Results

Q1 2016 financial performance in line with guidanceCDC notifies the Company of its intent to award a follow-on BioThrax procurement contract on October 1, 2016In transitioning to the follow-on...
04. Mai 2016 16:15 ET | Quelle: Emergent Biosolutions, Inc.

Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available

GAITHERSBURG, May 04, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM...
26. April 2016 16:15 ET | Quelle: Emergent Biosolutions, Inc.

Emergent Biosolutions to Participate in the Bank of America Merrill Lynch Healthcare Conference in May 2016

GAITHERSBURG, Md., April 26, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the Bank of...
21. April 2016 16:15 ET | Quelle: Emergent Biosolutions, Inc.

Emergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call on May 5, 2016

GAITHERSBURG, Md., April 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 5, 2016 at 5:00 pm (Eastern Time) to discuss the...
20. April 2016 09:00 ET | Quelle: Emergent Biosolutions, Inc.

Emergent BioSolutions Presents Preclinical Data on ES425 a Bispecific Immunotherapeutic Protein for Triple-Negative Breast Cancer

GAITHERSBURG, Md., April 20, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it presented preclinical data on its bispecific ADAPTIRTM (modular protein...

Vorherige Seite